MS Speaks

Multiple Sclerosis => TREATMENTS => Topic started by: agate on November 20, 2021, 09:43:09 pm

Title: Tecfidera vs Gilenya, Rituxan vs Tysabri compared
Post by: agate on November 20, 2021, 09:43:09 pm

From JAMA (November 16, 2021)--"Comparison of dimethyl fumarate vs fingolimod and rituximab vs natalizumab for treatment of multiple sclerosis":


https://bit.ly/3FBGAJU


Quote
Findings:  This comparative effectiveness study integrated electronic health records with research registry data and found no significant differences in relapse outcomes between dimethyl fumarate and fingolimod after correcting for confounding biases. Rituximab was associated with a lower relapse rate when compared with natalizumab after bias correction.